Skip to main content
BEYFORTUS 100 mg/mL injection by Sanofi Vaccines US Inc.
BEYFORTUS, 100 mg/mL, injection Drug class: Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody. Available on prescription only. Listed by Sanofi Vaccines US Inc..
Prescription only

BEYFORTUS

nirsevimab

Listed by Sanofi Vaccines US Inc.

Strength
100 mg/mL
Form
Injection
Route
Intramuscular
Class
Respiratory Syncytial Virus Anti-F Protein Mo…

What it contains

  • Nirsevimab 100 mg/mL

FDA record

Dosage form Injection
Route Intramuscular
Drug class Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody
Approval route BLA — biologic licence
NDC code 49281-574
FDA application BLA761328
RxNorm concept 2642406
Package sizes listed 2
Marketed since July 2023

Other products containing Nirsevimab

See all

Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.

BEYFORTUS

nirsevimab

Strength
100 mg/mL
Form
Injection
Class
Respiratory Syncytial Virus Anti-F Prot…
Rx only

Sanofi Vaccines US Inc.

Not stocked by us — reference only

Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.